Ignite Creation Date:
2024-05-06 @ 9:46 AM
Last Modification Date:
2024-10-26 @ 12:19 PM
Study NCT ID:
NCT03076372
Status:
UNKNOWN
Last Update Posted:
2018-02-27
First Post:
2017-03-01
Brief Title:
A Study Evaluating MM-310 in Patients With Solid Tumors
Sponsor:
Merrimack Pharmaceuticals
Organization:
Merrimack Pharmaceuticals
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Soft Tissue Sarcoma |
| Solid Tumors |
| Urothelial Carcinoma |
| Gastric Carcinoma |
| Squamous Cell Carcinoma of the Head and Neck |
| Ovarian Cancer |
| Pancreatic Ductal Adenocarcinoma |
| Prostate Adenocarcinoma |
| Non-small Cell Lung Cancer |
| Small Cell Lung Cancer |
| Triple Negative Breast Cancer |
| Endometrial Carcinoma |
Keywords:
| Name | View |
|---|---|
| Cancer | View |
| Oncology | View |
| Phase I | View |
| Gemcitabine | View |
| Carboplatin | View |
| MM-310 | View |
| EphA2 | View |
| Ephrin A2 | View |
| Solid tumors | View |
| urothelial carcinoma | View |
| gastric carcinoma | View |
| squamous cell carcinoma of the head and neck | View |
| ovarian cancer | View |
| pancreatic ductal adenocarcinoma | View |
| prostate adenocarcinoma | View |
| non-small cell lung cancer | View |
| small cell lung cancer | View |
| triple negative breast cancer | View |
| endometrial carcinoma | View |
| soft tissue sarcoma | View |
| Merrimack | View |